Aleix Prat: Biomarker-Driven Patient Selection Key in HR+/HER2+ Metastatic Breast Cancer
Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinic Hospital, shared a post on LinkedIn:
“Excited to share our new publication from the SOLTI-1303-PATRICIA trial (NCT02448420) at ESMO Open
‘Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B.’
Key findings (n=71 patients):
Median overall survival: 29.8 months (95% CI 20.9–38.0)
4-year OS: 13.3% (cohort A, ER–), 35.7% (cohort B1, ER+/no ET), 32.3% (cohort B2, ER+/letrozole)
PAM50 luminal subtypes: OS 38.0 vs. 26.6 months in non-luminal
Other biomarkers: luminal-related genes → better long-term survival; basal/proliferation-related genes → resistance
Higher luminal A, luminal B, and chemo-endocrine scores correlated with favorable prognosis
These results validate the potential of non-chemotherapy approaches in HR+/HER2+ metastatic breast cancer and emphasize the role of biomarker-driven patient selection.
Many thanks to all patients, investigators, and the SOLTI team for making this work possible.
Full article here.”
Title: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
Authors: T. Pascual, G. Villacampa, M. Oliveira, S. Escrivá-de-Romaní, S. Pernas, L. Paré, B. Adamo, E. Martínez, J. Cortés, A. Perelló, M. Galan, M. Melé, L. Villanueva, M. Gonzalez-Rodriguez, P. Tolosa, B. González-Farré, P. Galván, J. Canes, P. Nuciforo, J.M. Ferrero-Cafiero, X. González-Farré, P. Villagrasa, A. Prat, E. Ciruelos
More posts featuring Aleix Prat on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023